FDA Inspection 1327662 — Montefiore's Institute for Reproductive Medicine and Health
The FDA completed an inspection of Montefiore's Institute for Reproductive Medicine and Health on June 24, 2026 in Hartsdale, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- June 24, 2026
- Fiscal Year
- 2026
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Hartsdale, NY (United States)